Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Phase 2 Completed
68 enrolled 13 charts
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Phase 2 Completed
24 enrolled 9 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
Phase 2 Completed
55 enrolled 12 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Phase 2 Completed
34 enrolled 18 charts
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
Phase 2 Completed
185 enrolled 12 charts
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Phase 2 Completed
80 enrolled 56 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Phase 2 Completed
12 enrolled
INCB018424 in Patients With Advanced Hematologic Malignancies
Phase 2 Completed
51 enrolled 8 charts
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
150 enrolled 17 charts
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Phase 2 Completed
38 enrolled
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Phase 2 Completed
28 enrolled 10 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Phase 2 Completed
46 enrolled
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Phase 2 Completed
21 enrolled 14 charts
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Phase 2 Completed
33 enrolled 7 charts
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 2 Completed
61 enrolled 10 charts
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
155 enrolled 24 charts
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Phase 2 Completed
71 enrolled 13 charts
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Phase 2 Completed
112 enrolled
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2 Completed
7 enrolled 12 charts
PTBCy
Phase 2 Completed
50 enrolled
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Phase 2 Completed
111 enrolled 71 charts
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Phase 2 Completed
50 enrolled
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Phase 2 Completed
21 enrolled 24 charts
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Phase 2 Completed
40 enrolled
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Phase 2 Completed
32 enrolled 10 charts
FluBuBe
Phase 2 Completed
50 enrolled
UK-Haplo
Phase 2 Completed
77 enrolled
ICT-HCT
Phase 2 Completed
50 enrolled 12 charts
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Phase 2 Completed
22 enrolled 15 charts
FLAT-Auto
Phase 2 Completed
15 enrolled
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Phase 2 Completed
50 enrolled 23 charts
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Phase 2 Completed
14 enrolled 20 charts
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Phase 2 Completed
20 enrolled 17 charts
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
Phase 2 Completed
191 enrolled
SCT Plus Immune Therapy in Average Risk AML/MDS
Phase 2 Completed
26 enrolled
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Phase 2 Completed
25 enrolled
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase 2 Completed
202 enrolled 17 charts
Allo HSCT Using RIC for Hematological Diseases
Phase 2 Completed
156 enrolled
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Phase 2 Completed
127 enrolled 20 charts
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
Phase 2 Completed
14 enrolled